Merck KGaA shores up Rebif defenses to fend off new MS rivals

Save

Merck KGaA's multiple sclerosis treatment Rebif is holding its own. Considering that the German drugmaker's flagship product faces some formidable new competitors–including Biogen Idec's brand-new powerhouse, Tecfidera–that's not too shabby.